Resveratrol promotes myenteric neuroprotection in the ileum of rats after ischemia-reperfusion injury

Life Sciences

Volumn 166, Issue , 2016, Pages 54-59

  Borges, Stephanie Carvalho ^a   da Silva de Souza, Aline Cristine ^a   Beraldi, Evandro José ^a   Schneider, Larissa Carla Lauer ^a   Buttow, Nilza Cristina ^a  

^a STATE UNIVERSITY OF MARINGÁ   (Brazil)

Author keywords

Glial cells; Neuronal hypertrophy; nNOS IR; S100 IR; Superior mesenteric artery; VIP IR varicosities

Indexed keywords

NITRIC OXIDE SYNTHASE; RESVERATROL; VASOACTIVE INTESTINAL POLYPEPTIDE; ANTIOXIDANT; NEURONAL NITRIC OXIDE SYNTHASE; NEUROPROTECTIVE AGENT; STILBENE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DENSITY; GLIA CELL; ILEUM; INTESTINE ISCHEMIA; MALE; MORPHOMETRICS; MYENTERIC NEUROPROTECTION; MYENTERIC PLEXUS; NERVE CELL; NEUROPROTECTION; NITRERGIC NERVE CELL; NONHUMAN; RAT; REPERFUSION INJURY; SUPERIOR MESENTERIC ARTERY; VARICOSIS; ANIMAL; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECTS; GLIA; INNERVATION; PATHOLOGY; WISTAR RAT;

ANIMALS; ANTIOXIDANTS; CELL PROLIFERATION; ILEUM; MALE; MYENTERIC PLEXUS; NEUROGLIA; NEURONS; NEUROPROTECTION; NEUROPROTECTIVE AGENTS; NITRIC OXIDE SYNTHASE TYPE I; RATS; RATS, WISTAR; REPERFUSION INJURY; STILBENES;

EID: 84992331723     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2016.09.016     Document Type: Article

References (38)

1. [1] Mallick, I.H., et al. Ischemia-reperfusion injury of the intestine and protective strategies against injury. Dig. Dis. Sci. 49:9 (2004), 1359–1377.
2. [2] Taha, M.O., et al. Role of L-arginine, a substrate of nitric oxide biosynthesis, on intestinal ischemia-reperfusion in rabbits. Transplant. Proc. 42:2 (2010), 448–450.
3. [3] Todo, S., et al. Outcome analysis of 71 clinical intestinal transplantations. Ann. Surg. 222:3 (1995), 270–280 discussion 80-2.
4. [4] Haglund, U., Bergqvist, D., Intestinal ischemia – the basics. Langenbeck's Arch. Surg. 384:3 (1999), 233–238.
5. [5] Thornton, M., Solomon, M.J., Crohn's disease: in defense of a microvascular aetiology. Int. J. Color. Dis. 17:5 (2002), 287–297.
6. [6] Chang, R.W., et al. Update in management of mesenteric ischemia. World J. Gastroenterol. 12:20 (2006), 3243–3247.
7. [7] Granger, D.N., Korthuis, R.J., Physiologic mechanisms of postischemic tissue injury. Annu. Rev. Physiol. 57 (1995), 311–332.
8. [8] Stoney, R.J., Cunningham, C.G., Acute mesenteric ischemia. Surgery 114:3 (1993), 489–490.
9. [9] Lindeström, L.M., Ekblad, E., Structural and neuronal changes in rat ileum after ischemia with reperfusion. Dig. Dis. Sci. 49:7–8 (2004), 1212–1222.
10. [10] Piao, D.X., et al. Cytoplasmic delayed neuronal death in the myenteric plexus of the rat small intestine after ischemia. Arch. Histol. Cytol. 62:4 (1999), 383–392.
11. [11] da Silva de Souza, A.C., et al. Resveratrol reduces morphologic changes in the myenteric plexus and oxidative stress in the ileum in rats with ischemia/reperfusion injury. Dig. Dis. Sci. 60:11 (2015), 3252–3263.
12. [12] Rivera, L.R., et al. The reactions of specific neuron types to intestinal ischemia in the guinea pig enteric nervous system. Acta Neuropathol. 118:2 (2009), 261–270.
13. [13] Rivera, L.R., et al. Deleterious effects of intestinal ischemia/reperfusion injury in the mouse enteric nervous system are associated with protein nitrosylation. Cell Tissue Res. 344:1 (2011), 111–123.
14. [14] Calcina, F., et al. Effect of N-methyl-D-aspartate receptor blockade on neuronal plasticity and gastrointestinal transit delay induced by ischemia/reperfusion in rats. Neuroscience 134:1 (2005), 39–49.
15. [15] de la Lastra, C.A., Villegas, I., Resveratrol as an antioxidant and pro-oxidant agent: mechanisms and clinical implications. Biochem. Soc. Trans. 35:Pt 5 (2007), 1156–1160.
16. [16] Ergün, O., et al. Enteral resveratrol supplementation attenuates intestinal epithelial inducible nitric oxide synthase activity and mucosal damage in experimental necrotizing enterocolitis. J. Pediatr. Surg. 42:10 (2007), 1687–1694.
17. [17] Zhang, F., et al. Anti-inflammatory activities of resveratrol in the brain: role of resveratrol in microglial activation. Eur. J. Pharmacol. 636:1–3 (2010), 1–7.
18. [18] Sgambato, A., et al. Resveratrol, a natural phenolic compound, inhibits cell proliferation and prevents oxidative DNA damage. Mutat. Res. 496:1–2 (2001), 171–180.
19. [19] Virgili, M., Contestabile, A., Partial neuroprotection of in vivo excitotoxic brain damage by chronic administration of the red wine antioxidant agent, trans-resveratrol in rats. Neurosci. Lett. 281:2–3 (2000), 123–126.
20. [20] Sinha, K., et al. Protective effect of resveratrol against oxidative stress in middle cerebral artery occlusion model of stroke in rats. Life Sci. 71:6 (2002), 655–665.
21. [21] Wang, Q., et al. Resveratrol protects against global cerebral ischemic injury in gerbils. Brain Res. 958:2 (2002), 439–447.
22. [22] Frémont, L., Biological effects of resveratrol. Life Sci. 66:8 (2000), 663–673.
23. [23] Baur, J.A., Sinclair, D.A., Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov. 5:6 (2006), 493–506.
24. [24] Dudley, J., et al. Resveratrol, a unique phytoalexin present in red wine, delivers either survival signal or death signal to the ischemic myocardium depending on dose. J. Nutr. Biochem. 20:6 (2009), 443–452.
25. [25] Das, S., et al. Potentiation of a survival signal in the ischemic heart by resveratrol through p38 mitogen-activated protein kinase/mitogen- and stress-activated protein kinase 1/cAMP response element-binding protein signaling. J. Pharmacol. Exp. Ther. 317:3 (2006), 980–988.
26. [26] Wang, T., et al. Oxidative stress and hypoxia-induced factor 1α expression in gastric ischemia. World J. Gastroenterol. 17:14 (2011), 1915–1922.
27. [27] Köhler, H.F., et al. Enteral antioxidants in ischemia/reperfusion injuries in rats. Rev. Col. Bras. Cir. 38:6 (2011), 422–428.
28. [28] Liu, F.C., et al. Organ-protective effects of red wine extract, resveratrol, in oxidative stress-mediated reperfusion injury. Oxidative Med. Cell. Longev., 2015, 2015, 568634.
29. [29] Palombit, K., et al. Effects of ischemia and reperfusion on subpopulations of rat enteric neurons expressing the P2X7 receptor. Dig. Dis. Sci., 2013.
30. [30] Dong, Z., et al. Calcium in cell injury and death. Annu. Rev. Pathol. 1 (2006), 405–434.
31. [31] Kristián, T., Siesjö, B.K., Calcium in ischemic cell death. Stroke 29:3 (1998), 705–718.
32. [32] Delgado, M., et al. The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol. Rev. 56:2 (2004), 249–290.
33. [33] Misra, B.R., Misra, H.P., Vasoactive intestinal peptide, a singlet oxygen quencher. J. Biol. Chem. 265:26 (1990), 15371–15374.
34. [34] Masmoudi-Kouki, O., et al. Role of PACAP and VIP in astroglial functions. Peptides 28:9 (2007), 1753–1760.
35. [35] Tunçel, N., et al. The protective effect of vasoactive intestinal peptide (VIP) on stress-induced gastric ulceration in rats. Ann. N. Y. Acad. Sci. 865 (1998), 309–322.
36. [36] Tunçel, N., et al. Antioxidant and anti-apoptotic activity of vasoactive intestinal peptide (VIP) against 6-hydroxy dopamine toxicity in the rat corpus striatum. J. Mol. Neurosci. 46:1 (2012), 51–57.
37. [37] Delgado, M., Ganea, D., Vasoactive intestinal peptide prevents activated microglia-induced neurodegeneration under inflammatory conditions: potential therapeutic role in brain trauma. FASEB J. 17:13 (2003), 1922–1924.
38. [38] Marosti, A.R., et al. Differential effects of intestinal ischemia and reperfusion in rat enteric neurons and glial cells expressing P2X2 receptors. Histol. Histopathol. 30:4 (2015), 489–501.